Key result
Pretreatment with high-dose statins before percutaneous coronary intervention is supported by available evidence to reduce periprocedural myocardial infarction and microvascular injury.
Why the study?
Does pre-treatment with statins reduce periprocedural myocardial damage in patients undergoing percutaneous coronary intervention?
Population
Patients undergoing percutaneous coronary intervention (PCI)
Comparison
Pre-treatment with high-dose statins vs No statin pre-treatment or standard care
Design
Editorial
Authors
Loading...
Pre-treatment with high-dose statins before percutaneous coronary intervention is supported by evidence to reduce periprocedural myocardial damage, likely through pleiotropic anti-inflammatory effects.
Does pre-treatment with statins reduce periprocedural myocardial damage in patients undergoing percutaneous coronary intervention?
Pre-treatment with high-dose statins before percutaneous coronary intervention is supported by evidence to reduce periprocedural myocardial damage, likely through pleiotropic anti-inflammatory effects.
Habon et al. (2016) conducted an editorial in Cardiovascular disease requiring percutaneous coronary intervention. Statins was evaluated. Pretreatment with high-dose statins before percutaneous coronary intervention is supported by available evidence to reduce periprocedural myocardial infarction and microvascular injury.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: